Response Pattern and Modeling of Tumor Treating Fields

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F12%3A00007228" target="_blank" >RIV/00023884:_____/12:00007228 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Response Pattern and Modeling of Tumor Treating Fields

Popis výsledku v původním jazyce

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor, with a global incidence of approximately 3.5 per 100,000 people. Despite standard treatment consisting of surgical resection together with radiotherapy and concomitant/ adjuvant temozolomide chemotherapy, the median overall survival(OS)for patients with newly diagnosed GBM is only 12 to 18 months. Nearly all patients with GBM experience disease progression despite aggressive first-line therapy, with a median time to progression of 6 to 11 months. Treatment options for GBM at the time of recurrence are limited, and there is no widely accepted standard treatment. Thus, new and more effective treatment options are highly desirable.

Název v anglickém jazyce

Response Pattern and Modeling of Tumor Treating Fields

Popis výsledku anglicky

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor, with a global incidence of approximately 3.5 per 100,000 people. Despite standard treatment consisting of surgical resection together with radiotherapy and concomitant/ adjuvant temozolomide chemotherapy, the median overall survival(OS)for patients with newly diagnosed GBM is only 12 to 18 months. Nearly all patients with GBM experience disease progression despite aggressive first-line therapy, with a median time to progression of 6 to 11 months. Treatment options for GBM at the time of recurrence are limited, and there is no widely accepted standard treatment. Thus, new and more effective treatment options are highly desirable.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Alternating Electric Fields Therapy in Oncology

ISBN

978-3-319-30574-5

Počet stran výsledku

11

Strana od-do

55-65

Počet stran knihy

129

Název nakladatele

Springer International Publishing

Místo vydání

Basel

Kód UT WoS kapitoly

—